In contrast, the PARPi single agent may be promising to avoid chemotherapy in some patients as shown in the NEO TALA phase 3 trial, in which the talazoparib single agent in the neoadjuvant setting in early gBRCA1/2-mutated HER2-negative breast cancer achieved pCR rates comparable to those observed with the combination of anthracycline and taxane-based chemotherapy regimens. The gene discussed is ERBB2; the disease is breast cancer.